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The traditional Japanese medicine rikkunshito ameliorates the nitric oxide-associated delay in gastric emptying. Whether
rikkunshito aﬀects gastric motility associated with 5-hydroxytryptamine (serotonin: 5-HT) receptors or dopamine receptors is
unknown.Weexaminedthe eﬀects ofrikkunshitoonthe delayingastric emptying induced by5-HT ordopamineusingthe phenol
red method in male Wistar rats. 5-HT (0.01–1.0mgkg−1, i.p.) dose dependently delayed gastric emptying, similar to the eﬀect
of the 5-HT3 receptor agonist 1-(3-chlorophenyl) biguanide (0.01–1.0mgkg−1, i.p.). Dopamine also dose dependently delayed
gastricemptying. The5-HT3 receptor antagonistondansetron(0.04–4.0mgkg−1)andrikkunshito(125–500mgkg−1)signiﬁcantly
suppressed the delay in gastric emptying caused by 5-HT or 1-(3-chlorophenyl) biguanide. Hesperidin (the most active ingredient
inrikkunshito)suppressed the5-HT-induced delayedgastric emptying inadose-dependent manner,themaximumeﬀect ofwhich
was similar to that of ondansetron (0.4mgkg−1). The improvement obtained by rikkunshito or ondansetron in delaying gastric
emptying was completely blocked by pretreatment with atropine. Rikkunshito appears to improve delay in gastric emptying via
the antagonisticaction of the 5-HT3 receptor pathway.
1.Introduction
The traditional Japanese medicine rikkunshito is used in
Japan to treat various disorders of the gastrointestinal (GI)
tract [1–3]. Diseases associated with GI tract disorders
cause a range of symptoms such as abdominal fullness,
bloating, nausea, vomiting and postprandial early satiety, the
physiological mechanisms of which are critically involved
in GI motility disorders. It is hypothesized that rikkun-
shito may have an eﬀect on GI motility. In a previous
s t u d yb yo u rr e s e a r c hg r o u p ,r i k k u n s h i t ow a ss h o w nt o
ameliorate the delay in gastric emptying induced by NG-
nitro-l-arginine (an inhibitor of nitric oxide (NO) syn-
thase), and that its main active ingredient for improving
motility disorders of the stomach could be hesperidin,
identiﬁed from its methanol fraction by highly porous
polymer chromatography [4]. Gastrointestinal motility is
regulated not only by NO butalso various neurotransmitters
such as 5-hydroxytryptamine (5-HT: serotonin), dopamine,
catecholamines, histamine and acetylcholine. Investigating if
rikkunshito can aﬀect the GI motility associated with 5-HT
or dopamine pathways is crucialb e c a u s ev a r i o u sp r o k i n e t i c
agents aﬀecting 5-HT or dopamine receptors are often used
for diseases associated with GI motility disorders.
In the present study, we examined if rikkunshito and its
main active ingredient hesperidin could ameliorate the delay
in gastric emptying induced by 5-HT or dopamine.
2.Methods
2.1. Drugs and Chemicals. Rikkunshinto has eight con-
stituents: Glycyrrhizae radix (4.7%), Zingiberis rhizoma
(2.3%), Atractylodis lanceae rhizoma (18.6%), Zizyphi fruc-
tus (9.3%), Aurantii nobilis pericarpium (9.3%), Ginseng
radix (18.6%), Pinelliae tuber (18.6%) and Hoelen (18.6%).
Rikkunshito was obtained from Tsumura and Company
(Tokyo, Japan) as a dried powder extract. Rikkunshito was2 Evidence-Based Complementary and Alternative Medicine
extracted in hot water from a mixture of these eight con-
stituents. Rikkunshito used in this study was standardized
by the following three procedures: (i) identiﬁcation of
spots derived from the respective crude drugs by thin-
layer chromatography; (ii) evaluation of the amount of
absolute ethanol-soluble components: conform to item of
“Diethyl ether-soluble extract” in the “Extract content” in
the “Crude Drug Test” in the General Tests, Methods and
Apparatus described in the Japanese Pharmacopoeia; and
(iii) quantiﬁcation of the contents of glycyrrhizic acid and
hesperidin by liquid chromatography (no speciﬁed value has
been published by Tsumura & Co.). A voucher specimen
(number 2020043010) has been deposited in Tsumura
and Company. Ondansetron hydrochloride (Zofran injec-
tion) was purchased from GlaxoSmithKline (Middlesex,
UK). Mosapride citrate was kindly donated by Dainippon
Sumitomo Pharmaceutical Company (Osaka, Japan). 5-
HT 5-hydroxytryptamine hydrochloride: serotonin, atropine
sulfate salt, 1-(3-Chlorophenyl) biguanide hydrochloride,
phenol red and Tween-80 were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Hesperidin was obtained
from Tsumura and Company. In all in vivo experiments,
rikkunshito was dissolved in distilled water and admin-
istered (p.o.) in 10mlkg−1 into rats. Ondansetron and
atropine sulfate salt were dissolved in physiological (0.9%)
saline and injected (s.c,) in 2mlkg−1 into rats. 5-HT,
dopamine and 1-(3-chlorophenyl) biguanide were dissolved
in physiological saline and injected (i.p.) in 2mlkg−1 into
rats.
2.2. Animals. Animal experiments were carried out in
accordance with the institutional guidelines of Tsumura and
Company after obtaining permission from the Laboratory
Animal Committee and approval from the Animal Ethics
Committee of Osaka City University. Experiments were
designed to minimize the number of animals used and their
suﬀering.
Male Wistar rats (age 9 weeks) were obtained from Japan
SLC (Hamamatsu, Japan). Rats were allowed to acclimatize
to their surroundings for ≥1 week. They had free access to
water and standard laboratory food. They were maintained
in afacility ata temperatureof25 ± 1◦C,relative humidityof
55 ± 25%, and controlled lighting with lights on from 07:00
to 19:00h daily.
2.3. Measurement of Gastric Emptying in Rats. The experi-
mentwasconductedinaccordancewiththemethodreported
in our previous articles [4, 5]. Brieﬂy, rats were fasted
for 24h, and then 1ml of phenol red (0.1mgml−1)a sa
nonabsorbable marker was injected into the stomach of each
rat. Each rat was killed 15min after administration of phenol
red(exceptthosekilledimmediatelyafterinjectiontorecover
the entire dose of phenol red) and the stomach immediately
removed. The stomach was cut into several pieces in 10ml
of Na2HPO4 solution (0.1 moll−1) to collect the gastric
contents, including phenol red (S1 solution). One millilitre
of S1 solution was collected to determine the phenol red
concentration of S1 solution, and the residual S1 solution
added to 1ml of phenol red solution at 0.1mgml−1 to
prepare S2 solution. The absorbance values of S1 and S2
solutions were measured as optical density (OD)1 and OD2
at 560nm using a UV-1200 spectrophotometer (Shimadzu
Company, Kyoto, Japan). The rate of gastric emptying was
calculated as follows:
Amount of phenol red in stomach

µg

=

100 −S1
S2 −S1

× S1
(1)
Note: S1 ≤ OD1 > xa + b,S 2 ≤ OD2 > xa + b
 a  and  b  are coeﬃcients obtained from the standard
curve for phenol red.
Gastric emptying rate (%) = 100 −

A
B

×100 (2)
A: amount of phenol red remaining in each stomach (µg)
and B: amount of phenol red recovered from the stomach
immediately after administration of phenol red (µg).
2.4. Changes in Gastric Emptying by Various Drugs (5-HT, 5-
HT3 Agonist, 5-HT4 Agonists and Dopamine) in Rats. The
5-HT and the 5-HT3 agonist 1-(3-chlorophenyl) biguanide
at 0.01–1.0mgkg−1 were injected (i.p.) before administra-
tion of phenol red. The 5-HT4 agonist mosapride citrate
at 0.3–3.0mgkg−1 was administered (p.o.) 60min before
administration of phenol red. Dopamine (0.4mgkg−1, i.p.)
was injected immediately before administration of phenol
red according to previous report [6]. Each vehicle was
administered to control rats instead of 5-HT, 5-HT3 agonist,
5-HT4 agonist or dopamine using the same schedule. Gastric
emptying was evaluated using the method described above.
2.5. Therapeutic Eﬃcacy for the Delay in Gastric Emptying
Induced by 5-HT, Dopamine and a 5-HT3 Agonist [1-(3-
Chlorophenyl) biguanide] by Rikkunshito or Ondansetron
in Rats. According to previous reports [6], 5-HT
(0.02mgkg−1, i.p.) or dopamine (0.4mgkg−1, i.p.)
was injected immediately, and the 5-HT3 agonist 1-(3-
chlorophenyl) biguanide (0.4mgkg−1, i.p.) was injected
30min before administration of phenol red. Rikkunshito
(125, 250 or 500mgkg−1, p.o.) was administered 120min
before injection of 5-HT or dopamine, and 90min before
injection of 1-(3-chlorophenyl) biguanide. The human
dose of rikkunshito is 4g (converted to extract)/day, as
described in a book, “MAN-BYO-KAI-SHUN” (Wan bing
hui chun). For a human adult weighing 60kg, the dose
is 4000mg/60kg = 66.6mgkg−1;a1 0 × higher dose in
rats becomes 666.6mgkg−1. Accordingly, the upper limit
dose was set at 500mgkg−1 in this study. Ondansetron
(0.04, 0.4 or 4.0mgkg−1, s.c.) was injected 30min before
injection of 5-HT or dopamine, and immediately before
injection of 1-(3-chlorophenyl) biguanide. Distilled water
was administered or vehicle was injected to control rats
instead of rikkunshito or ondansetron under the same
schedule. Gastric emptying was evaluated using the method
described above.Evidence-Based Complementary and Alternative Medicine 3
2.6. Improvement of the 5-HT-Induced Delay in Gastric
Emptying by Hesperidin in Rats. Hesperidin (0.3, 1.0 or
3.0mgkg−1, p.o.) was administered 120min before injection
of5-HT(0.02mgkg−1, i.p.). Distilled water was injected into
control rats instead of hesperidin under the same schedule.
2.7. Pretreatment with Atropine and Inhibition of the
Improvement of the 5-HT-Induced Delay in Gastric Emptying
by Rikkunshito or Ondansetron. 5-HT (0.02mgkg−1)w a s
injected immediately before administration of phenol red.
In the case of atropine treatment, atropine (1mgkg−1)
was injected 120min before injection of 5-HT. Rikkunshito
(500mgkg−1, p.o.) was administered 120min before injec-
tion of 5-HT, and ondansetron (0.4mgkg−1, s.c.) injected
30min before injection of 5-HT into rats.
2.8.StatisticalAnalysis. Valuesareexpressedasmean±SEM.
The signiﬁcance of diﬀerences between groups was evalu-
ated using Student’s t-test or one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple comparison test.
P < .05 were considered signiﬁcant.
3.Results
3.1. Amelioration of the 5-HT- and Dopamine-Induced Delay
in Gastric Emptying by Rikkunshito in Rats. We initially
reconﬁrmed the delay in gastric emptying induced by injec-
tionof5-HT(0.02mgkg−1,i.p.)anddopamine(0.4mgkg−1,
i.p.), which was consistent with previous reports [6].
Rikkunshito administration at a high dose of 500mgkg−1
amelioratedthe5-HT-induced delayingastric emptying, but
rikkunshito at a lower dose (125 or 250mgkg−1)d i dn o t
(Figure 1(a)). Rikkunshito at any of the doses used did not
reverse the delay caused by dopamine (Figure 1(b)).
3.2. Changes in Gastric Emptying by 5-HT, 5-HT3 [1-(3-
Chlorophenyl) biguanide] and 5-HT4 (Mosapride) Agonists
in Rats. Intraperitoneal injection of 5-HT signiﬁcantly
delayed gastric emptying compared with controls in a dose-
dependent manner (controls, 81.7 ± 4.5%; at 0.1 and
1.0mgkg−1, 50.2 ± 8.8 and 38.5 ± 4.3%). The 5-HT3 ago-
nist, 1-(3-Chlorophenyl)biguanide also signiﬁcantly delayed
gastric emptying in a dose-dependent manner similar to the
eﬀects of 5-HT (from 78.8 ± 3.1 to 40.2 ± 6.4%), whereas
the 5-HT4 agonist mosapride at 0.3–3.0mgkg−1 accelerated
it from 75.6 ± 5.7 to 90.7 ± 2.3% (Figure 2).
3.3. Amelioration of the 5-HT- and Dopamine-Induced
Delay in Gastric Emptying by 5-HT Receptor Antagonists
(Ondansetron) in Rats. The 5-HT3 receptor antagonist
ondansetron at 0.4 and 4.0mgkg−1 signiﬁcantly ameliorated
the 5-HT-induced delay in gastric emptying (Figure 3(a)),
b u ti td i dn o ta ﬀect the delay induced by dopamine
(Figure 3(b)). These ﬁndings suggest that intraperitoneal
injection of 5-HT acts on the type-3 receptor of 5-HT.
3.4. Improvement of the 5-HT Agonist [1-(3-Chlorophenyl)
biguanide]-Induced Delay in Gastric Emptying by Rikkunshito
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Figure 1: Amelioration of the 5-HT- (a) and dopamine-induced
(b) delay in gastric emptying by rikkunshito in rats: (a) rikkunshito
administration at a high dose of 500mgkg−1 ameliorated the 5-HT
(0.02mgkg−1)-induced delay in gastric emptying, but rikkunshito
at a lower dose (125 or 250mgkg−1)d i dn o t ;( b )r i k k u n s h i t oa t
any of the doses used in this study did not reverse the delay caused
by dopamine (0.4mgkg−1); each column represents the mean ±
SEM. of eight rats. ∗P < .01: signiﬁcantlydiﬀerent from the control
group.
and Ondansetron. To clarify the pharmacological eﬀect of
rikkunshito on the 5-HT3 receptor, we examined the eﬀects
of rikkunshito or ondansetron (reference arm) on the 5-
HT3 agonist-induced delay in gastric emptying. The delay
induced by intraperitoneal injection of the 5-HT3 agonist 1-
(3-chlorophenyl) biguanide at 0.4mgkg−1 (from ∼80% to
35–40%) was suppressed by rikkunshito administration in
a dose-dependent manner (Figure 4(a)). Like rikkunshito,
pretreatment with ondansetron signiﬁcantly ameliorated
delay of gastric emptying in a dose-dependent manner
(Figure 4(b)).
3.5. Improvement of the 5-HT-Induced Delay in Gastric Emp-
tying by Hesperidin. Administration of hesperidin (one of
ingredients extracted from rikkunshito), which ameliorated
the delay in gastric emptying by a NO synthase inhibitor
in the previous report, suppressed the 5-HT-induced delay
in gastric emptying in a dose-dependent manner (Figure 5).
High-dose hesperidin (3.0mgkg−1)s h o w e das i m i l a re ﬀect
to that of ondansetron (0.4mgkg−1) for this delay.4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Changes in gastric emptying by 5-HT, 5-HT3,1 - ( 3 -
chlorophenyl) biguanide, and 5-HT4 (mosapride) agonists in rats:
intraperitonealinjectionof5-HT (0.1and1.0mgkg−1)signiﬁcantly
delayed gastric emptying compared with the controls (from 81.7 ±
4.5to50.2±8.8and38.5±4.3%)inadose-dependentmanner.The
5-HT3 agonist 1-(3-chlorophenyl) biguanide signiﬁcantly delayed
gastric emptying,similarto 5-HT (from78.8 ± 3.1 to 40.2 ± 6.4%),
whereasthe 5-HT4 agonistmosapride(0.3–3.0mgkg−1) accelerated
it (from 75.6 ± 5.7 to 90.7 ± 2.3%). Each column represents the
mean ± SEM.ofeight rats. ∗P < .01:signiﬁcantlydiﬀerent from the
control group.
3.6. Inhibition of the Improvement of the 5-HT-Induced
Delay in Gastric Emptying by Rikkunshito or Ondansetron
by Pretreatment with Atropine. There was no eﬀect of
pretreatment with atropine alone at 1mgkg−1 on 5-HT-
induced delay in gastric emptying. The improvement on
5-HT-induced delay in gastric emptying by rikkunshito or
ondansetron was completely blocked by pretreatment with
atropine (Figure 6).
4.Discussion
In the present study, we demonstrated that rikkunshito and
hesperidin (the most active ingredient in rikkunshito) could
improve the 5-HT-induced delay in gastric emptying in rats,
the mechanism of which appears to involve the antagonistic
action of the 5-HT3 receptor pathway.
Recently,integrative and complementary studiesdemon-
strated various additional eﬀects such as anti-inﬂammatory
and anti-tumor eﬀects of present therapeutic medicines and
natural substances via targets for particular molecules [7, 8].
Those studies have critical signiﬁcances in gastroenterology,
a n dw er e p o r t e dt h ea n t i b a c t e r i a le ﬀect of the Japanese
herbal medicine, gosyuyu (wu-chu-yu) against Helicobacter
pylori, in vitro and in vivo [9, 10]. Several studies show
that Japanese herbal medicines including rikkunshito have
ac l i n i c a le ﬃcacy for functional dyspepsia (FD) via improve-
ment of GI motility disorders [11, 12]. However, there are
a few evidences which demonstrated the pharmacological
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Figure 3: Amelioration of the 5-HT- (a) and dopamine-induced
(b) delay in gastric emptying by ondansetron in rats: (A) adminis-
tration of ondansetron (0.4 or 4.0mgkg−1)a m e l i o r a t e dt h e5 - H T
(0.02mgkg−1)-induced delay in gastric emptying; (B) ondansetron
atanyofthedosesusedinthisstudydidnotreversethedelaycaused
by dopamine (0.4mgkg−1). Each column represents the mean ±
SEM of eight rats. ∗∗P < .01, ∗P < .05: signiﬁcantly diﬀerent from
the control group.
function of rikkunshito like this, although, recently, a part
of pharmacological mechanism(s) and active ingredients of
rikkunshito have been elucidated [4, 13].
Gastric motility-like emptying and accommodation is
regulated at various levels such as NO, 5-HT and its
receptors. Many clinically useful drugs aﬀect gastric motility
via NO or 5-HT type-3 or type-4 receptors. It has also
been reported that rikkunshito has a prokinetic action
mediated by NO [4, 13, 14]. If rikkunshito has another
pharmacological action than that described above, it may
prove that rikkunshito has an alternative signiﬁcance in
gastric motility similar to the combined eﬃcacy of severalEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Improvement in the 5-HT3 agonist [1-(3-chlorophenyl)
biguanide]-induced delay in gastric emptying by rikkunshito
(a) and ondansetron (b): the delay induced by intraperitoneal
injection of the 5-HT3 agonist 1-(3-Chlorophenyl) biguanide at
0.4mgkg−1 (from ∼80 to 35–40%) was suppressed by rikkunshito
administration in a dose-dependent manner (a). Like rikkunshito,
pretreatment with ondansetron signiﬁcantly ameliorated delay of
gastric emptying in a dose-dependent manner (b). Each column
represents the mean ± SEM of eight rats. ∗∗P < .01, ∗P < .05:
signiﬁcantlydiﬀerent from the control group.
drugs. In our previous study, rikkunshito could ameliorate
the delay in gastric emptying induced by an inhibitor of NO
synthase: NG-nitro-l-arginine [4]. Initially, the mechanism
was thought to be mediated via NO production alone
because rikkunshito includes l-arginine, a substrate of NO,
initswaterfraction. This hypothesis appearsto besupported
by previous contributions that showed that rikkunshito
promotes NO-associated gastric adaptive relaxation in iso-
lated guinea-pig stomach [13, 14]. Analysis for fractional
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Figure 5: Improvement in the 5-HT-induced delay in gastric
emptying by hesperidin: administration of hesperidin (one of
the ingredients extracted from rikkunshito) improved the 5-HT-
induced delay in gastric emptying in a dose-dependent manner.
Hesperidin at a high dose (3.0mgkg−1) showed a similar eﬀect to
that of ondansetron (0.4mgkg−1) for this delay, but hesperidin at a
lower dose(0.3or1.0mgkg−1) did not. Each columnrepresents the
mean ± SEM of eight rats. ∗∗P < .05: signiﬁcantly diﬀerent from
the control group.
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Figure 6: Inhibition of the improvement in 5-HT-induced delay in
gastric emptying by rikkunshito and ondansetron by pretreatment
with atropine: there was no eﬀect of pretreatment with atropine
alone at 1mgkg−1 on 5-HT-induced delay in gastric emptying. The
improvementin5-HT-induced delayingastricemptyingbyrikkun-
shito and ondansetron was completely blocked by pretreatment
with atropine. Each column represents the mean ± SEM of eight
rats. ∗∗P < .01: signiﬁcantly diﬀerent from each paired group.
extracts of rikkunshito revealed that there was a more potent
ingredient (hesperidin) in the methanol fraction than the
crude water fraction or l-arginine alone, which promotes
gastric motility [4]. It was reported that hesperidin is
not a substrate of NO because of a non-member of the
guanidine group [15] and that it decreases NO production
[16]. It was therefore demonstrated that rikkunshito and6 Evidence-Based Complementary and Alternative Medicine
hesperidin had more potential to promote gastric motility
mediated via a mechanism other than the NO-associated
mechanism. These ﬁndings allow us to elucidate the eﬀect of
rikkunshito on gastric motility disorders associated with 5-
HT and dopamine because these neurotransmitters (as well
as NO) have a signiﬁcant role in gastric motility and various
prokinetic agents aﬀecting 5-HT receptors or dopamine
receptors which are often used to treat GI motility disorders.
Intraperitoneally injected 5-HT fails to cross the blood-
brain barrier [17]. It is therefore likely that 5-HT binds
to any 5-HT receptors located on vagal aﬀerent ﬁbers and
enteric nerves, resulting in a delay of gastric emptying
[18]. Of the seven types of 5-HT receptors previously
identiﬁed, the 5-HT3 and 5-HT4 receptors participate in
the regulation of sensory and motor functions of the
GI tract [19, 20]. Injection of the 5-HT3 agonist 1-(3-
chlorophenyl) biguanide delayed gastric emptying, whereas
the 5-HT4 agonist mosapride accelerated gastric emptying
in rats. Rikkunshito, hesperidin and the 5-HT3 receptor
antagonist ondansetron ameliorated the5-HT-induced delay
in gastric emptying, whereas the 5-HT4 receptor antagonist
SB204070 had no eﬀect (data not shown). Rikkunshito
could not aﬀect the delay induced by dopamine. This
suggests that the eﬀect of rikkunshito on gastric motility
was not non-speciﬁc. The present eﬃcacy of rikkunshito in
enhancing gastric motility may be mediated by other sub-
stances, including catecholamines, histamine, acetylcholine
and ghrelin. Rikkunshito may be associated with ghrelin in
the promotion of gastric motility because it can elevate the
low levels of plasma ghrelin induced by cisplatin [21]. It
was also reported that the dose of 5-HT used in the present
study could not change the peripheral secretion and gastric
production of ghrelin [21]. The pharmacological action of
rikkunshito in promoting gastric motility indicated in the
present study may therefore not be associated with ghrelin.
It was reported that the 13 crude components contained in
rikkunshito had no binding activity with the 5-HT3 receptor
[21]. Pretreatment with atropine completely blocked the
rikkunshito- and ondansetron-induced improvements in
gastric emptying inthe5-HT-induceddelaymodel described
above. The 5-HT3 antagonistic eﬀect on increased gastric
motility is mediated by acetylcholine release, which leads
to contraction of smooth muscle. Therefore, it appears that
rikkunshito (like ondansetron) has 5-HT3 antagonist eﬀects
on gastric motility. Taken together, these ﬁndings suggest
that rikkunshito and hesperidin may ameliorate the delay in
gastric emptying in rats via the antagonistic action of the 5-
HT3 receptor pathway, but not 5-HT4 receptor (Figure 7).
Moreover, the eﬃcacy of rikkunshito and hesperidin may
appear to be a partial eﬀect compared to that of ondansetron
in this model, because their eﬀects on the gastric emptying
seemed to be weaker than that of ondansetron. However,
there were no statistical signiﬁcances between the nor-
mal and rikkunshito (500mgkg−1) groups, and hesperidin
(3.0mgkg−1) showed a similar recovery in gastric emptying
to ondansetron (0.4mgkg−1). Thus, these slight diﬀerences
among rikkunshito, hesperidinand ondansetron are thought
to be derived from the diﬀerences in selectivity for the 5-
HT3 receptor pathway. It cannot be concludedwith certainty
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Figure 7: A scheme of improvement of the 5-HT-induced delay in
gastric emptying by rikkunshito.
that rikkunshito has a pharmacological eﬀect on any site of
the 5-HT3 receptor pathway because the signal transduction
pathway after binding of the speciﬁc agonist of the 5-HT3
receptor or direct eﬀects of the agents on various molecules
associated with this signal have not been elucidated [22,
23]. A major limitation of the present study was that the
signal transduction pathway or targeted molecules after
binding of the speciﬁc agonist of the 5-HT3 receptor has
not been elucidated. We therefore could not pursue the
detailed target molecules for rikkunshito through the 5-
HT3 receptor pathway. On the other hand, it is known that
other active ingredients for gastric motility are included
in rikkunshito, such as 6-gingesulfonic acid, shogasulfonic
acid A and atractylodin [24, 25]. However, rikkunshito
consists of over a 100 compounds, and proportion of several
active components of rikkunshito is small. Therefore, it
is diﬃcult for an appropriate isolation to examine each
pharmacological function in vivo.T h u s ,w ec o u l dn o t
check the eﬀect of all compounds on gastric motility. The
main purpose of this study was to investigate whether
rikkunshito aﬀects gastric motility via the 5-HT pathway.
Therefore, we have examined the eﬀects of rikkunshito
and hesperidin, the most active components of rikkunshito
(Figure 8).
In general, it has been shown that prokinetic drugs
are useful for patients with FD in a meta-analysis for
prokinetic drugs using mainly cisapride [26, 27]. Prokinetic
drugs are not established in the therapeutic strategy for FD
patients. The reason may be that the currently available
prokinetic drugs cannot comprehensively regulate gastric
motility, including gastric accommodation and emptying.
Diﬀerent from other prokinetic drugs that have a single
pharmacological action, rikkunshito has at least a possibility
to accelerate gastric accommodation and emptying mediated
by the NO and 5-HT3 receptor pathway. Rikkunshito could
therefore be an alternative candidate drug for prokinetic
drugs such as itopride and mosapride; this hypothesis is
supported by previous clinical articles [28–30]. In general,
a herbal medicine like rikkunshito has not been a ﬁrstlyEvidence-Based Complementary and Alternative Medicine 7
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Figure 8: Three dimensionalanalysis for rikkunshito by high performance liquid chromatography.
chosen candidate for various diseases, since it is consisted
of multiple components whose pharmacological function
and active ingredients have not been elucidated in detail.
Therefore, rikkunshito has been recognized to be only
a complementary and alternative drug. However, some
recent basic researches and established evidences about
rikkunshito might demonstrate not only an impact as a
complementary and alternative drug but also new clinical
beneﬁts as a standardized drug.
In conclusion, we demonstrated that rikkunshito and
hesperidin (a potent ingredient of rikkunshito), showed
pharmacological eﬃcacy in enhancing gastric motility via
antagonism of the 5-HT3 receptor-associated pathway.
Rikkunshito may thus prove useful in improving abdom-
inal symptoms caused by motility dysfunction in human
patients.
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